Provided by Tiger Fintech (Singapore) Pte. Ltd.

Mersana Therapeutics Inc.

0.3977
-0.0023-0.57%
Post-market: 0.3878-0.0099-2.49%19:29 EDT
Volume:1.57M
Turnover:606.55K
Market Cap:49.57M
PE:-0.70
High:0.4099
Open:0.4067
Low:0.3751
Close:0.4000
Loading ...

Mersana Therapeutics Announces Positive Initial Clinical Data from Phase 1 Clinical Trial of Emiltatug Ledadotin (XMT-1660); Initiation of Expansion in Triple Negative Breast Cancer

GlobeNewswire
·
10 Jan

Analysts Offer Insights on Healthcare Companies: ACELYRIN, INC. (SLRN), Cabaletta Bio (CABA) and Mersana Therapeutics (MRSN)

TIPRANKS
·
15 Nov 2024

Truist Financial Reaffirms Their Buy Rating on Mersana Therapeutics (MRSN)

TIPRANKS
·
14 Nov 2024

Mersana Therapeutics Inc (MRSN) Q3 2024 Earnings Call Highlights: Strategic Advances and ...

GuruFocus.com
·
14 Nov 2024

Q3 2024 Mersana Therapeutics Inc Earnings Call

Thomson Reuters StreetEvents
·
14 Nov 2024

Mersana Therapeutics Shares Climb 23% After 3Q Results Beat Estimates

Dow Jones
·
14 Nov 2024

Mersana Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary

Reuters
·
13 Nov 2024

BRIEF-Mersana Therapeutics Provides Business Update And Announces Q3 2024 Financial Results

Reuters
·
13 Nov 2024

Mersana Therapeutics, Inc. (MRSN) Reports Q3 Loss, Tops Revenue Estimates

Zacks
·
13 Nov 2024

BRIEF-Mersana Therapeutics Q3 EPS USD -0.09

Reuters
·
13 Nov 2024

Mersana Therapeutics Q3 EPS USD -0.09

THOMSON REUTERS
·
13 Nov 2024

Mersana Therapeutics: Cash, Cash Equivalents & Marketable Securities as of September 30, 2024, Were $155.2 Mln

THOMSON REUTERS
·
13 Nov 2024

Mersana Therapeutics Inc expected to post a loss of 18 cents a share - Earnings Preview

Reuters
·
11 Nov 2024

Mersana Therapeutics to Host Third Quarter 2024 Conference Call on November 13, 2024

GlobeNewswire
·
06 Nov 2024